<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Yi J</submitter><funding>U.S. Department of Health &amp;amp; Human Services | NIH | National Cancer Institute</funding><funding>NCI NIH HHS</funding><pagination>1941</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC10079682</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>14(1)</volume><pubmed_abstract>Since Mdm2 (Mouse double minute 2) inhibitors show serious toxicity in clinic studies, different approaches to achieve therapeutic reactivation of p53-mediated tumor suppression in cancers need to be explored. Here, we identify the USP2 (ubiquitin specific peptidase 2)-VPRBP (viral protein R binding protein) axis as an important pathway for p53 regulation. Like Mdm2, VPRBP is a potent repressor of p53 but VPRBP stability is controlled by USP2. Interestingly, the USP2-VPRBP axis also regulates PD-L1 (programmed death-ligand 1) expression. Strikingly, the combination of a small-molecule USP2 inhibitor and anti-PD1 monoclonal antibody leads to complete regression of the tumors expressing wild-type p53. In contrast to Mdm2, knockout of Usp2 in mice has no obvious effect in normal tissues. More</pubmed_abstract><journal>Nature communications</journal><pubmed_title>Targeting USP2 regulation of VPRBP-mediated degradation of p53 and PD-L1 for cancer therapy.</pubmed_title><pmcid>PMC10079682</pmcid><funding_grant_id>R35CA253059</funding_grant_id><funding_grant_id>R01 CA258390</funding_grant_id><funding_grant_id>R01 CA254970</funding_grant_id><funding_grant_id>R01 CA227450</funding_grant_id><funding_grant_id>CA227450</funding_grant_id><funding_grant_id>RO1CA258390</funding_grant_id><funding_grant_id>RO1CA254970</funding_grant_id><funding_grant_id>R35 CA253059</funding_grant_id><funding_grant_id>P30 CA013696</funding_grant_id><pubmed_authors>Yi J</pubmed_authors><pubmed_authors>Li H</pubmed_authors><pubmed_authors>Wang D</pubmed_authors><pubmed_authors>Gu W</pubmed_authors><pubmed_authors>Baer RJ</pubmed_authors><pubmed_authors>Tavana O</pubmed_authors></additional><is_claimable>false</is_claimable><name>Targeting USP2 regulation of VPRBP-mediated degradation of p53 and PD-L1 for cancer therapy.</name><description>Since Mdm2 (Mouse double minute 2) inhibitors show serious toxicity in clinic studies, different approaches to achieve therapeutic reactivation of p53-mediated tumor suppression in cancers need to be explored. Here, we identify the USP2 (ubiquitin specific peptidase 2)-VPRBP (viral protein R binding protein) axis as an important pathway for p53 regulation. Like Mdm2, VPRBP is a potent repressor of p53 but VPRBP stability is controlled by USP2. Interestingly, the USP2-VPRBP axis also regulates PD-L1 (programmed death-ligand 1) expression. Strikingly, the combination of a small-molecule USP2 inhibitor and anti-PD1 monoclonal antibody leads to complete regression of the tumors expressing wild-type p53. In contrast to Mdm2, knockout of Usp2 in mice has no obvious effect in normal tissues. More</description><dates><release>2023-01-01T00:00:00Z</release><publication>2023 Apr</publication><modification>2026-04-30T13:04:53.291Z</modification><creation>2024-11-21T02:02:18.611Z</creation></dates><accession>S-EPMC10079682</accession><cross_references><pubmed>37024504</pubmed><doi>10.1038/s41467-023-37617-3</doi></cross_references></HashMap>